Skip to content

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06353594
Acronym
COPERNICAN
Enrollment
1272
Registered
2024-04-09
Start date
2024-03-11
Completion date
2035-09-30
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevation Myocardial Infarction

Keywords

STEMI

Brief summary

The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with ST-segment myocardial infarction (STEMI). Randomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. Random allocation in a 1:1 fashion to one of the following strategies: * Study group: reduced stent PCI strategy (DCB-based) * Control group: conventional PCI strategy (DES-based).

Interventions

Coronary percutaneous revascularization

Sponsors

Jorge Sanz Sanchez
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients presenting with STEMI and indication to undergo pPCI.

Exclusion criteria

* Life expectancy \<1 year due 1 to non-cardiac disease. * Inability to provide informed consent. * Cardiogenic shock. * Left ventricular ejection fraction \<15%. * Left main disease. * Stent thrombosis * Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions). * Patients with chronic total occlusions. * Untreatable coronary disease. * Non-identified culprit lesion. * Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.

Design outcomes

Primary

MeasureTime frameDescription
Target lesion failure (TLF)12 monthsTarget-vessel myocardial infarction or ischemia-driven target-lesion revascularization

Secondary

MeasureTime frameDescription
Incidence of myocardial infarction10 yearsPhysicians Assessment
Incidence of cardiovascular death10 yearsPhysicians Assessment
Incidence of target lesion revascularization10 yearsPhysicians Assessment
Incidence of stent thrombosis10 yearsPhysicians Assessment
Incidence of all-cause death10 yearsPhysicians Assessment
Incidence of stroke10 yearsPhysicians Assessment
Incidence of acute kidney injury10 yearsPhysicians Assessment
Incidence of bleeding10 yearsPhysicians Assessment
Incidence of acute vessel closure10 yearsPhysicians Assessment

Countries

Spain

Contacts

Primary ContactNaiara García Lamas
naiara@pinvestiga.com634213101
Backup ContactMarta Fernández Álvarez
marta@pinvestiga.com604037828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026